RA CAPITAL MANAGEMENT, L.P.
CIK 1346824
13F filing for Q2 2026・No. 516
- Holdings
- US$11.51B
- Quarter change
- +US$2.07B
- Entries
- 85
- Net bought (estimate)
- +US$1.19B
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 17
- Sold out 18
- Cut 10
- Added 10
- Corporate actions 0
- Unchanged 47
Largest holdings
84 stocks worth US$11.51B, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| ASCENDIS PHARMA A/SCommon Stock | New | 10,281,496 | US$2.74B | 23.83% |
| PARABILIS MEDICINES INCCommon Stock | New | 28,933,371 | US$791.91M | 6.88% |
| RYTMRHYTHM PHARMACEUTICALS INCCommon Stock | Unchanged | 6,666,837 | US$740.22M | 6.43% |
| PCVXVAXCYTE INCCommon Stock | Unchanged | 11,474,599 | US$667.02M | 5.80% |
| SIONNA THERAPEUTICS INCCommon Stock | Unchanged | 9,905,045 | US$435.72M | 3.79% |
| TYRA BIOSCIENCES INCCommon Stock | Unchanged | 12,198,625 | US$389.62M | 3.39% |
| EDGEWISE THERAPEUTICS INCCommon Stock | Cut | 8,392,730 | US$341M | 2.96% |
| NAMSNEWAMSTERDAM PHARMA CO NVCommon Stock | Unchanged | 9,550,191 | US$323.66M | 2.81% |
| COAGHEMAB THERAPEUTICS HOLDINGSCommon Stock | New | 7,808,627 | US$286.81M | 2.49% |
| SEPTERNA INCCommon Stock | Unchanged | 6,995,858 | US$234.29M | 2.04% |
Sign in (free) to see its 50 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 14, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.